{"product_id":"obeda-semaglutide-injection-2-mg-1-5-ml-1-34-mg-ml-pre-filled-pen-with-needles","title":"OBEDA® Semaglutide Injection 2 mg\/1.5 mL (1.34 mg\/mL) Prefilled Pen – Dr. Reddy’s","description":"\u003ch2\u003eProduct Introduction\u003c\/h2\u003e\n\u003cp\u003eOBEDA® is a prescription-only injectable medicine containing \u003cspan\u003esemaglutide\u003c\/span\u003e, a glucagon-like peptide-1 (GLP-1) receptor agonist. Manufactured in India by Dr. Reddy’s Laboratories Limited, the product is supplied as a prefilled pen containing 1.5 mL of solution equivalent to 2 mg of semaglutide.\u003c\/p\u003e\n\u003cp\u003eThe pack indicates selectable doses of 0.25 mg and 0.5 mg, with dose delivery in these increments only. It is intended for subcutaneous administration according to a specialist's prescription. The packaging states that the pen is for single-patient use only and includes six BD Ultra-Fine™ 32G needles and product literature.\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eImportant:\u003c\/span\u003e The package specifically warns that the medicine is to be sold by retail only on the prescription of an endocrinologist or internal medicine specialist. Dispensing and use must follow the applicable prescription and regulatory requirements.\u003c\/p\u003e\n\u003ch2\u003eUses\u003c\/h2\u003e\n\u003cp\u003eSemaglutide medicines may be prescribed for specific metabolic conditions, depending on the approved indication for the particular product and local prescribing information.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eBlood glucose management:\u003c\/span\u003e Semaglutide is used in certain formulations to improve glycaemic control in adults with type 2 diabetes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eMetabolic management:\u003c\/span\u003e Some semaglutide formulations have an approved role in chronic weight management for eligible patients. This indication must not be assumed for OBEDA without confirmation from its current Indian prescribing information.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eSpecialist-directed treatment:\u003c\/span\u003e The exact indication, suitability and treatment plan must be determined by the prescribing specialist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDo not use OBEDA for type 1 diabetes or diabetic ketoacidosis unless a specialist is addressing a separate, specifically indicated clinical need. It is not a substitute for insulin when insulin is medically required.\u003c\/p\u003e\n\u003ch2\u003eKey Ingredients \u0026amp; Full Ingredients\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eActive ingredient\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eSemaglutide: 1.34 mg per mL.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eEach 1.5 mL prefilled pen contains a total of 2 mg semaglutide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eInactive ingredients listed on the packaging\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eDisodium phosphate dihydrate: 1.42 mg per mL.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003ePropylene glycol: 14.0 mg per mL.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003ePhenol: 5.50 mg per mL.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eWater for injection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eHydrochloric acid or sodium hydroxide may be added to adjust pH.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eThe amounts above are transcribed from the supplied packaging images. Confirm the complete formulation against the package insert before publishing or dispensing.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eBenefits\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eProvides semaglutide in a prefilled injection pen for subcutaneous administration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eOffers selectable 0.25 mg and 0.5 mg doses as indicated on the packaging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eUses a GLP-1 receptor agonist to support glucose-dependent insulin secretion and glucose regulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eMay help improve blood glucose control when prescribed for an appropriate indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe pen format and included needles support administration according to the product instructions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eIncludes product literature for patient guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eBenefits depend on the approved indication, prescribed dose, adherence and individual response. Results are not guaranteed.\u003c\/p\u003e\n\u003ch2\u003eSide Effects\u003c\/h2\u003e\n\u003cp\u003ePotential adverse effects of semaglutide include:\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eCommon effects\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eNausea and vomiting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eDiarrhoea or constipation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eAbdominal discomfort, bloating or indigestion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eReduced appetite.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eSerious effects requiring prompt medical assessment\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003ePersistent or severe abdominal pain, which may indicate pancreatitis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eSevere or persistent vomiting or diarrhoea, which can cause dehydration and kidney problems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eSymptoms of gallbladder disease, such as upper abdominal pain, fever or jaundice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eAllergic reactions, including facial or throat swelling or difficulty breathing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eHypoglycaemia, particularly when used with insulin or sulfonylureas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eSudden changes in vision in a patient with diabetes, which warrant urgent clinical review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis is not a complete list. Refer to the current package insert and seek medical advice about any new or worsening symptoms.\u003c\/p\u003e\n\u003ch2\u003eProduct Form\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e Sterile solution for injection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePresentation:\u003c\/span\u003e Prefilled injection pen.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eStrength:\u003c\/span\u003e 2 mg\/1.5 mL (1.34 mg\/mL).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eAdministration route:\u003c\/span\u003e Subcutaneous injection only.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePack contents:\u003c\/span\u003e One semaglutide prefilled pen, six BD Ultra-Fine™ 32G needles and product literature, as stated on the pack.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePatient use:\u003c\/span\u003e Single-patient use only.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eHow to Use\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eObtain a valid prescription.\u003c\/span\u003e Use only under the supervision of the specialist specified on the packaging.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eRead the medication guide.\u003c\/span\u003e Review the instructions supplied with the pen and have a pharmacist or healthcare professional demonstrate its use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eCheck the pen.\u003c\/span\u003e Confirm the medicine name, strength, expiry date, solution appearance and package integrity. Do not use it if the seal is broken before first use or the solution appears abnormal.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eFollow the prescribed dose.\u003c\/span\u003e The pack identifies 0.25 mg and 0.5 mg dose increments. Do not independently select a dose, increase the dose or change the treatment schedule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eAdminister subcutaneously.\u003c\/span\u003e Use only the approved injection sites and technique described in the product instructions. Do not inject into a vein or muscle.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eUse a new needle for each injection.\u003c\/span\u003e Never share the pen, even if the needle is changed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eDispose of the needle safely.\u003c\/span\u003e Use an appropriate sharps container and follow local disposal guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cspan\u003eMissed dose, dose changes and overdose:\u003c\/span\u003e Follow the official patient leaflet and contact the prescribing specialist or pharmacist for advice. Do not take an extra dose to compensate for a missed one.\u003c\/p\u003e\n\u003ch2\u003eHow It Works\u003c\/h2\u003e\n\u003cp\u003eSemaglutide mimics the activity of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone involved in glucose regulation and appetite signalling.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eGlucose-dependent insulin secretion:\u003c\/span\u003e Helps the pancreas release insulin when blood glucose is elevated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eGlucagon regulation:\u003c\/span\u003e Reduces inappropriate glucagon secretion, helping limit excess glucose production by the liver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eGastric emptying:\u003c\/span\u003e Can slow stomach emptying, particularly early in treatment, which may affect post-meal glucose levels and gastrointestinal tolerance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eAppetite signalling:\u003c\/span\u003e Acts on pathways involved in appetite and satiety.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese effects can contribute to improved blood glucose control in appropriately selected patients. The clinical effects and approved uses depend on the specific product, its prescribing information and the patient's condition.\u003c\/p\u003e\n\u003ch1\u003e3. Medical \u0026amp; Safety Information\u003c\/h1\u003e\n\u003ch2\u003eSafety Advice\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePrescription requirement:\u003c\/span\u003e The package states that retail sale is restricted to prescriptions from an endocrinologist or internal medicine specialist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePregnancy:\u003c\/span\u003e Semaglutide is generally not recommended during pregnancy. Anyone who is pregnant, planning pregnancy or breastfeeding should discuss treatment with their specialist before use. Semaglutide is generally discontinued at least two months before a planned pregnancy; the prescriber must advise on the appropriate plan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eBreastfeeding:\u003c\/span\u003e Obtain specialist advice because product-specific information and the clinical circumstances determine whether treatment is appropriate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eAlcohol:\u003c\/span\u003e Alcohol may complicate blood glucose management and may worsen gastrointestinal symptoms. Discuss alcohol consumption with the treating clinician, especially when taking other glucose-lowering medicines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eDriving and operating machinery:\u003c\/span\u003e Semaglutide alone is not generally expected to impair driving directly, but hypoglycaemia can occur when it is combined with insulin or sulfonylureas. Do not drive if dizzy, unwell or experiencing low blood glucose.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eKidney conditions:\u003c\/span\u003e Severe vomiting or diarrhoea can lead to dehydration and worsening kidney function. Patients with kidney disease require appropriate medical monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eLiver conditions:\u003c\/span\u003e Discuss existing liver disease and all other medical conditions with the prescriber; do not assume the medicine is suitable without an individual assessment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003ePancreatitis:\u003c\/span\u003e Tell the specialist about any history of pancreatitis. Seek urgent assessment for persistent, severe abdominal pain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eGallbladder disease:\u003c\/span\u003e Report previous gallstones or gallbladder problems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eDiabetic eye disease:\u003c\/span\u003e Patients with diabetic retinopathy or sudden changes in vision should inform their specialist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eThyroid tumour risk:\u003c\/span\u003e Discuss any personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) with the prescriber. Semaglutide product warnings and contraindications must be checked against the applicable Indian prescribing information.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eChildren:\u003c\/span\u003e Keep the pen and needles out of children's reach. Use in children only if specifically authorised by the applicable product information and specialist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eQuick Tips\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eStore the unopened pen in a refrigerator at \u003cspan\u003e2°C to 8°C\u003c\/span\u003e. Do not freeze.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eAccording to the supplied pack, after first use the pen may be stored for \u003cspan\u003e56 days\u003c\/span\u003e at a temperature not exceeding 30°C or in a refrigerator at 2°C to 8°C.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eProtect the pen from inappropriate storage conditions and follow the complete leaflet for light exposure and handling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eNever share the pen with another person.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eKeep a record of the prescribed dose and injection schedule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eMaintain any recommended nutrition, physical activity and blood glucose monitoring plan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003eContact the prescriber before combining semaglutide with other diabetes medicines or changing an existing treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFact Box\u003c\/h2\u003e\n\u003cdiv\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003cth\u003e\n\u003cp\u003eAttribute\u003c\/p\u003e\n\u003c\/th\u003e\n\u003cth\u003e\n\u003cp\u003eDetails\u003c\/p\u003e\n\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eBrand\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eOBEDA®\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eActive ingredient\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eSemaglutide\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eStrength\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e2 mg\/1.5 mL (1.34 mg\/mL)\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eProduct form\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eSterile solution in a prefilled pen\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eRoute\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eSubcutaneous\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003ePack quantity\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e1 prefilled pen\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eIncluded accessories\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003e6 BD Ultra-Fine™ 32G needles\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eTherapeutic class\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eGLP-1 receptor agonist\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003ePrescription status\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003ePrescription-only; specialist prescription specified on pack\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eHabit forming\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eStorage before first use\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eRefrigerate at 2°C–8°C; do not freeze\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eStorage after first use\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eUp to 56 days, at ≤30°C or 2°C–8°C, as stated on pack\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003ePatient use\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eSingle patient only\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eManufacturer\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eDr. Reddy’s Laboratories Limited\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003eManufacturing licence number\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp\u003eKTK\/28A\/0919\/2023\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp\u003e\u003cspan\u003eDietary restrictions:\u003c\/span\u003e There is no universal food restriction solely because of semaglutide, but a clinician may recommend an individual meal plan. Follow any dietary advice provided for the underlying condition.\u003c\/p\u003e\n\u003ch2\u003eInteraction with Drugs\u003c\/h2\u003e\n\u003cp\u003eImportant interactions and precautions include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eInsulin and sulfonylureas:\u003c\/span\u003e May increase the risk of hypoglycaemia; the prescriber may need to adjust doses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eOther semaglutide products or GLP-1 receptor agonists:\u003c\/span\u003e Do not combine without explicit specialist direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eMedicines taken by mouth:\u003c\/span\u003e Delayed gastric emptying may affect the absorption or timing of certain oral medicines. Discuss medicines requiring close monitoring with a pharmacist.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eWarfarin and other medicines requiring monitoring:\u003c\/span\u003e Additional monitoring may be appropriate when changes in gastrointestinal function or food intake could affect treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eMedicines associated with dehydration or kidney stress:\u003c\/span\u003e Severe gastrointestinal side effects may increase the risk of kidney complications, particularly in vulnerable patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eProvide the prescriber with a complete list of prescription medicines, over-the-counter products and supplements. Do not stop or adjust any medicine without professional advice.\u003c\/p\u003e\n\u003ch1\u003e4. Business Details\u003c\/h1\u003e\n\u003ch2\u003eManufacturer, Importer, and Marketer\u003c\/h2\u003e\n\u003cp\u003e\u003cspan\u003eManufacturer details (transcribed from the supplied packaging):\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eManufactured in India by:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eDr. Reddy's Laboratories Limited,\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eC\/o M\/s One Source Speciality Pharma Ltd,\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePlot no. 2-D1, Obandenahalli, Doddaballapura 3rd Phase,\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eIndustrial Area, Doddaballapura Taluk, Bengaluru Rural 561203.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eM.L. No.: KTK\/28A\/0919\/2023\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eBrand:\u003c\/span\u003e OBEDA®\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eManufacturer:\u003c\/span\u003e Dr. Reddy’s Laboratories Limited\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eImporter:\u003c\/span\u003e Not identified on the supplied packaging images.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eMarketer:\u003c\/span\u003e A separate marketer is not identified on the supplied packaging images.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cdiv\u003e\n\u003cdiv\u003e\n\u003cp\u003e\u003cspan\u003eWebsite:\u003c\/span\u003e \u003cspan\u003e\u003ca href=\"https:\/\/www.imedicart.com\/\"\u003eiMEDICART.com\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003ePackaging warning:\u003c\/span\u003e “To be sold by retail on the prescription of endocrinologist or internal medicine specialists only.”\u003c\/p\u003e\n\u003cp\u003eThe manufacturer details above are transcribed from the supplied images. Verify the legal manufacturer name, address, current licence details and any additional importer or marketer information against the physical pack before publishing the listing.\u003c\/p\u003e\n\u003ch1\u003e5. FAQs\u003c\/h1\u003e\n\u003ch3\u003e1. What is OBEDA Semaglutide Injection used for?\u003c\/h3\u003e\n\u003cp\u003eOBEDA contains semaglutide, a GLP-1 receptor agonist. Semaglutide is used in certain approved formulations for type 2 diabetes and, for some specific products, chronic weight management. Confirm OBEDA's exact approved indication with the prescribing specialist and its current Indian package insert.\u003c\/p\u003e\n\u003ch3\u003e2. What strengths or doses are shown on the OBEDA pack?\u003c\/h3\u003e\n\u003cp\u003eThe pack states a total content of 2 mg semaglutide in 1.5 mL, at a concentration of 1.34 mg\/mL. It also identifies selectable doses of 0.25 mg and 0.5 mg. The prescribed dose and schedule must be determined by the specialist.\u003c\/p\u003e\n\u003ch3\u003e3. How should OBEDA be stored?\u003c\/h3\u003e\n\u003cp\u003eStore the pen refrigerated at 2°C–8°C before first use and do not freeze it. The supplied packaging states that after first use it may be stored for 56 days at a temperature not exceeding 30°C or in a refrigerator at 2°C–8°C. Follow the complete leaflet for any additional storage requirements.\u003c\/p\u003e\n\u003ch3\u003e4. What are the common side effects of semaglutide?\u003c\/h3\u003e\n\u003cp\u003eCommon side effects include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. Severe persistent abdominal pain, allergic reactions, dehydration or sudden changes in vision require prompt medical assessment.\u003c\/p\u003e\n\u003ch3\u003e5. Can OBEDA be used without a prescription?\u003c\/h3\u003e\n\u003cp\u003eNo. The packaging specifically restricts retail sale to prescriptions from an endocrinologist or internal medicine specialist. It should not be self-prescribed or used solely for weight loss without specialist assessment.\u003c\/p\u003e","brand":"Dr Reddy's Laboratories Ltd","offers":[{"title":"Default Title","offer_id":67948124537055,"sku":null,"price":3780.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0631\/1952\/4063\/files\/OBEDA_Semaglutide_Injection_2_mg_1.5_mL_Prefilled_Pen_Front_View.png?v=1791613617","url":"https:\/\/www.imedicart.com\/hi\/products\/obeda-semaglutide-injection-2-mg-1-5-ml-1-34-mg-ml-pre-filled-pen-with-needles","provider":"iMediCart E Pharmacy","version":"1.0","type":"link"}